Takeda Pharmaceutical Company Reports Positive Topline Results from Pivotal Phase 2/3 Study of TAK-881 in Primary Immunodeficiency Disease
Takeda Pharmaceutical Company (TSE:4502/NYSE:TAK) has reported positive topline results from its pivotal Phase 2/3 clinical trial, TAK-881-3001, evaluating an investigational immunoglobulin therapy for patients with primary immunodeficiency disease (PID). The study successfully met its primary endpoint, demonstrating pharmacokinetic (PK) comparability between TAK-881 and the currently approved therapy HYQVIA. In addition, secondary outcomes confirmed comparable safety, efficacy, and tolerability profiles, reinforcing the potential of TAK-881 as a next-generation treatment option for patients requiring long-term immunoglobulin replacement therapy.
Primary immunodeficiency diseases encompass a group of rare disorders in which part of the body’s immune system is missing or functions improperly. Individuals living with PID are particularly vulnerable to recurrent infections, which can be severe and, in some cases, life-threatening. For many of these patients, immunoglobulin (IG) replacement therapy remains the cornerstone of treatment, providing the antibodies necessary to protect against infections. However, while effective, traditional IG therapies often impose a substantial treatment burden due to the need for frequent infusions, large infusion volumes, and lengthy administration times.
Takeda’s investigational therapy, TAK-881, is designed to address these challenges. It is a subcutaneous immunoglobulin (SCIG) 20% solution facilitated with recombinant human hyaluronidase, an enzyme that temporarily enhances tissue permeability, allowing larger volumes of immunoglobulin to be delivered subcutaneously. This approach enables less frequent dosing and potentially reduces the number of infusion sites required, thereby improving convenience for patients.
The TAK-881-3001 study evaluated multiple parameters, including pharmacokinetics, efficacy, safety, tolerability, and immunogenicity. The trial enrolled both adult and pediatric patients aged two years and older who had previously received IG therapy. The investigational therapy was compared with HYQVIA, a well-established SCIG 10% therapy facilitated with hyaluronidase, in patients aged 16 years and older.
Results from the trial demonstrated that TAK-881 achieved pharmacokinetic equivalence to HYQVIA, meeting the study’s primary endpoint. Specifically, the geometric mean ratio for immunoglobulin G (IgG) exposure—measured as the area under the concentration-time curve over a dosing interval at steady state—was 99.67%, with a 90% confidence interval ranging from 95.10% to 104.46%. These findings confirm that TAK-881 delivers comparable levels of circulating antibodies, a critical factor in ensuring adequate immune protection for patients.
Beyond pharmacokinetics, the study also showed that TAK-881 provided effective immune protection, as evidenced by infection rates comparable to those observed with HYQVIA. Patients maintained protective IgG levels consistently throughout the study, demonstrating that the investigational therapy can sustain the immune defense required to prevent infections in individuals with PID.
Safety and tolerability outcomes further supported the potential of TAK-881. The therapy exhibited a safety profile similar to that of HYQVIA, with no new safety signals identified during the trial. This is particularly important in the context of chronic conditions like PID, where patients require lifelong treatment and long-term safety is a critical consideration. Takeda noted that the safety profile of TAK-881 will continue to be monitored in an ongoing extension study, TAK-881-3002, to further evaluate its long-term use.
One of the most promising aspects of TAK-881 lies in its ability to deliver the required immunoglobulin dose in a more efficient manner. Because it is formulated as a 20% solution, TAK-881 can provide the same therapeutic dose as HYQVIA using approximately half the infusion volume. This reduction in volume has the potential to significantly shorten infusion times, making treatment more convenient and less disruptive to patients’ daily lives. Additionally, the therapy supports flexible dosing schedules, allowing administration as infrequently as once every three or four weeks, depending on patient needs.
Kristina Allikmets, Senior Vice President and Head of Plasma-Derived Therapies Research and Development at Takeda, emphasized the importance of these findings. She noted that the study demonstrates TAK-881’s ability to match the pharmacokinetic performance of an established standard of care while offering practical advantages such as fewer injection sites, shorter infusion durations, and flexible dosing intervals. According to her, the results reflect Takeda’s broader commitment to advancing innovative immunoglobulin therapies that improve patient experience without compromising safety or efficacy.
The burden associated with lifelong immunoglobulin therapy remains a significant challenge for patients with PID. Frequent infusions, long administration times, and the need for careful management can impact quality of life, limiting daily activities and adding to the psychological and logistical demands of chronic disease management. As such, there is a strong need for therapies that not only maintain clinical effectiveness but also reduce the overall treatment burden.
Richard L. Wasserman, an allergist and immunologist who served as the principal investigator for the TAK-881-3001 trial, highlighted this perspective. He pointed out that improving the administration process can have a meaningful impact on patients’ lives, making treatment more manageable and less intrusive. The results from the study, he explained, suggest that a highly concentrated, hyaluronidase-facilitated subcutaneous immunoglobulin therapy like TAK-881 can provide effective immune protection while offering a more patient-friendly infusion experience.
Takeda continues to analyze data from the TAK-881-3001 study and plans to present additional findings at upcoming medical conferences. These analyses are expected to provide further insights into the therapy’s performance across different patient populations and clinical scenarios. The company is also advancing its regulatory strategy, with plans to submit applications for TAK-881 to health authorities in the United States, European Union, and Japan during fiscal year 2026.
If approved, TAK-881 could represent an important addition to the treatment landscape for primary immunodeficiency diseases. By combining robust clinical efficacy with a more convenient and efficient mode of administration, the therapy has the potential to address longstanding challenges associated with immunoglobulin replacement therapy. This aligns with a broader trend in healthcare toward patient-centered innovation, where improving quality of life is considered as important as achieving clinical outcomes.
In summary, the positive results from the TAK-881-3001 trial mark a key milestone for Takeda and for the field of immunology. The demonstration of pharmacokinetic comparability, along with strong safety and efficacy data, supports the continued development of TAK-881 as a promising new option for patients with PID. As the company moves forward with regulatory submissions and further clinical evaluation, the therapy could play a pivotal role in reshaping how immunoglobulin treatments are delivered, offering patients a more streamlined and manageable approach to lifelong care.
About TAK-881-3001 and TAK-881-3002
TAK-881-3001 was a pivotal Phase 2/3 clinical trial evaluating the pharmacokinetics, efficacy, safety, tolerability and immunogenicity of TAK-881 in adults and pediatric patients aged 2 years and older with Primary Immunodeficiency Disease (PID) who were previously treated with immunoglobulin (IG) therapy.
Study participants aged 16 and older were randomized to be treated with TAK-881 followed by HYQVIA or HYQVIA followed by TAK-881 with the same dose and dosing interval of IG for up to 51 weeks in the open label, randomized cross-over study part. Participants aged 2 to < 16 were treated with only TAK-881 for up to 27 weeks in the open label single-arm study part. Further information about the TAK-881-3001 clinical trial is available at ClinicalTrials.gov under study identifier NCT05755035.
TAK-881-3002 is a Phase 3 study evaluating the long-term safety and tolerability of TAK-881 in patients with PID and is the extension study of TAK-881-3001. Further information about the TAK-881-3002 clinical trial is available at ClinicalTrials.gov under study identifier NCT06076642.
About TAK-881
TAK-881 [Immune Globulin Subcutaneous (Human), 20% Solution (SCIG 20%) and Recombinant Human Hyaluronidase] is an investigational liquid medicine comprised of one vial of immunoglobulin (IG) 20% and one vial of Halozyme’s recombinant human hyaluronidase (rHuPH20). IG is collected from human plasma and maintains the body’s immune system.
TAK-881 is infused under the skin into the fatty subcutaneous tissue where the hyaluronidase facilitates the dispersion and increases the absorption of immunoglobulin in the subcutaneous tissue, allowing larger volumes to be infused at a given infusion site. As a SCIG 20% facilitated with hyaluronidase, TAK-881 is being developed with the goal of reducing infusion volume and duration while providing effective immune protection for patients with PID.
About Primary Immunodeficiency Disease (PID)
Primary Immunodeficiency Disease (PID) is a group of more than 550 rare and chronic disorders, where a part of the body’s immune system is missing or does not function the way it should.1 These conditions result from genetic mutations, which are usually inherited.2 The symptoms of PID vary and can include frequent and/or persistent infections and unusual autoimmunity, often leading to prolonged periods of misdiagnosis despite consultations with multiple specialists.3 In the United States, PID affects about 1 in 1,200 people.4
About HYQVIA®
HYQVIA® [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] is a liquid medicine containing immunoglobulin (IG) 10% and Halozyme’s recombinant human hyaluronidase (rHuPH20).
HYQVIA is approved by the European Medicines Agency (EMA) as a replacement therapy in adults, children and adolescents (0-18 years) with Primary Immunodeficiency Disease (PID) with impaired antibody protection and with Secondary Immunodeficiency Disease (SID) in patients who suffer from severe or recurrent infections, ineffective antimicrobial treatment, and either proven specific antibody failure (PSAF) or serum IgG level of <4 g/L. In addition, it is approved by the EMA in adults, children and adolescents (0-18 years) with chronic inflammatory demyelinating polyneuropathy (CIDP) as maintenance therapy after stabilization with intravenous IG therapy (IVIG).
In the United States HYQVIA is approved to treat adults and children two years of age and older with PID as a well as a maintenance therapy for adult patients with CIDP.
HYQVIA is infused under the skin into the fatty subcutaneous tissue and contains IG collected from human plasma. IGs are antibodies that maintain the body’s immune system. The hyaluronidase part of HYQVIA facilitates the dispersion and absorption of IG in the subcutaneous space between the skin and the muscle. HYQVIA is infused up to once a month (every two, three or four weeks for CIDP; every three or four weeks for PID).
